Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prolab

This article was originally published in The Tan Sheet

Executive Summary

GNC to carry more than 20 Natrol sports nutrition products for first time, manufacturer announces May 22. Prolab gondola display will be used at retail chain's 4,500 stores under multi-year deal, which Natrol expects to be first stage of long-term relationship with GNC. Ads will note availability of Prolab supplements at GNC outlets and brand's logo will be featured in GNC's NASCAR sponsorship promotions. Natrol, which hopes to attract more casual exercisers in addition to dedicated athletes, says new products, such as EcdyVone anabolic accelerator slated for summer debut, will be highlighted. Products will accompany GNC store brands and offerings from other marketers, such as Twinlab and Weider - both of which have reported declining sales to GNC stores (1"The Tan Sheet" April 9, p. 7 and 2Jan. 15, p. 12)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel